GSK Studying whether the vaccine with optimal pebbles reduces the risk of dementia
General view outside Glaxosmithkline (GSK) in Brondford, London, Britain, May 4 2020 – Reuters London: GSK said on Tuesday that it is studying a group of more than one million elderly adults in the United Kingdom to examine whether its best -selling vaccine reduces the risk of dementia. The British pharmacist uses the health data of about 1.4 million people, aged 65 to 66 years, some of whom received the SHingrix Shot and some who did not. GSK chief scientific employee Tony Wood said that the data, from the large NHS database (NHS), is a unique set of information, because
